68Ga-DOTATOC PET for Treatment Efficacy Evaluation of Cardiac Sarcoidosis

Clin Nucl Med. 2020 Sep;45(9):e416-e418. doi: 10.1097/RLU.0000000000003185.


Cardiac sarcoidosis (CS) has a poor prognosis related to life-threating arrhythmias and heart failure. Treatment includes anti-inflammatory therapies and implantable pacemaker and/or cardioverter defibrillator. The presence of cardiac devices and physiologic myocardial glucose uptake are major limitations of both cardiac magnetic resonance and F-FDG PET/CT, reducing their diagnostic value. Somatostatin-based PET/CT has been proposed to detect active CS. Contrarily to F-FDG uptake, which reflects nonspecific leukocyte infiltration, Ga-DOTATOC may identify active granulomatosis. Herein, we underline the specificity of Ga-DOTATOC PET in challeging clinical situations including refractory CS, and chronic CS in patients with cardiac device, or false-positive F-FDG PET/CT results.

MeSH terms

  • Adult
  • Aged
  • Cardiomyopathies / diagnostic imaging*
  • Cardiomyopathies / therapy*
  • False Positive Reactions
  • Female
  • Fluorodeoxyglucose F18
  • Humans
  • Male
  • Middle Aged
  • Octreotide / analogs & derivatives*
  • Organometallic Compounds*
  • Positron Emission Tomography Computed Tomography
  • Positron-Emission Tomography*
  • Sarcoidosis / diagnostic imaging*
  • Sarcoidosis / therapy*
  • Sensitivity and Specificity
  • Treatment Outcome


  • Organometallic Compounds
  • Fluorodeoxyglucose F18
  • Octreotide